Q-omics provides the consensus-scored ALAS2 profile across patient tissues and cancer cell-line models. ALAS2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ALAS2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, ALAS2 RNA expression shows 8,476 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, COAD, and TGCT as cancer lineages where ALAS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALAS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALAS2 survival associations across molecular data types. ALAS2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALAS2 RNA expression–survival associations across cancer types. High ALAS2 expression shows unfavorable associations in MESO, COAD, LUAD and BLCA, but favorable associations in KIRC and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ALAS2 RNA expression.
This table summarizes ALAS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ALAS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALAS2 shows lower tumor expression in COAD, LUSC, LUAD, THCA, BRCA and PAAD. The COAD box plot shows higher ALAS2 RNA expression in normal versus tumor tissue (log2 FC = −0.522, t-test p < 0.001).
This table shows molecular features associated with ALAS2 in patient tissues and cancer cell lines. In patient samples, ALAS2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ALAS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
